" class="no-js "lang="en-US"> Erik Digman Wiklund - Medtech Alert
Thursday, March 28, 2024
Erik Digman Wiklund

Erik Digman Wiklund

About Erik Digman Wiklund

Related Story

Targovax Announces That the FDA Has Granted Authorization to Initiate Clinical Trials With the Enhanced TG01 RAS Vaccine in the USA

June 23 2022

Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]

Targovax Announces Clinical Collaboration With Agenus for Upcoming ONCOS-102 Phase 2 Melanoma Trial

May 12 2022

Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]

Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted with QS-21 STIMULON™

March 8 2022

Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, […]

Targovax ASA Strengthens Management with Lubor Gaal as Chief Financial Officer

February 28 2022

Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]

Targovax ASA Appoints Dr. Erik Digman Wiklund as New CEO

October 20 2021

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid […]